{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053875","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.893182+00:00","generated_at":"2026-06-09T21:51:08.061630+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid sells 13% of soticlestat royalties & milestones to Ligand for $30M; cash runway into 2026","bullets":["Ligand pays Ovid $30M (non-dilutive) for 13% of soticlestat regulatory/commercial milestones and tiered royalties (low double-digits to 20%).","Ovid retains 87% of soticlestat economic interest; Takeda funds all development and has no further obligations for Ovid.","Cash runway extended into 2026 (from into 2025), enabling expansion of pipeline of rare epilepsy and anti-seizure programs.","Soticlestat is in two pivotal Phase 3 trials for Lennox-Gastaut and Dravet syndromes; Takeda anticipates regulatory filings in FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053875","json":"https://secwatch.observer/filing/0000950170-23-053875.json","markdown":"https://secwatch.observer/filing/0000950170-23-053875.md","text":"https://secwatch.observer/filing/0000950170-23-053875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023053875/0000950170-23-053875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023053875/ovid-20231017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:51:08.061630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac4226334ede4e058cfdd76f6c887977bec25dce","claim":"Ovid Therapeutics Inc. entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $30 million (effective 2023-10-17).","evidence_excerpt":"On October 17, 2023, Ovid Therapeutics Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”):","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023053875/0000950170-23-053875-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Ligand Pharmaceuticals Incorporated"},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2023-10-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}